-
公开(公告)号：US20150044225A1
公开(公告)日：2015-02-12
申请号：US14505515
申请日：2014-10-03
Inventor： Kazuyoshi Ikuta , Ritsuko Koketsu , Yoshinobu Okuno , Mikihiro Yunoki , Shoji Ideno , Masatoshi Oshita , Motoki Kuhara , Masatoshi Momota
IPC: C07K16/10
CPC classification number: C07K16/1018 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/34 , C07K2317/76
Abstract: Provided is a human antibody having a neutralization activity against a human influenza virus. More specifically, provided is a human antibody which recognizes a highly conserved region in a human influenza A virus subtype H3N2 or a human influenza B virus and has a neutralization activity against the virus. The human antibody is a human anti-human influenza virus antibody, which has a neutralization activity against a human influenza A virus subtype H3N2 and binds to a hemagglutinin HA1 region of the human influenza A virus subtype H3N2, or which has a neutralization activity against a human influenza B virus, and includes, as a base sequence of a DNA encoding a variable region of the antibody, a sequence set forth in any one of SEQ ID NOS: 5 to 12.
Abstract translation: 本发明提供对人流感病毒具有中和活性的人抗体。 更具体地，提供了识别人流感A型病毒亚型H3N2或人类流感B型病毒中的高度保守区域并具有针对病毒的中和活性的人抗体。 人抗体是人抗流感病毒抗体，其对人甲型流感病毒亚型H3N2具有中和活性，并与人甲型流感病毒亚型H3N2的血凝素HA1区域结合，或者具有中和活性 人流感B病毒，并且作为编码抗体可变区的DNA的碱基序列，包含SEQ ID NO：5〜12中任一项所述的序列。
-
公开(公告)号：US20210261964A1
公开(公告)日：2021-08-26
申请号：US17260418
申请日：2019-07-18
Applicant: THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY , OSAKA UNIVERSITY , TEIKYO UNIVERSITY
Inventor： Taiki AOSHI , Shohei KOYAMA , Ryo SUZUKI
IPC: C12N15/117 , A61K9/107 , A61K31/7088 , A61K47/28 , A61K47/24 , A61K47/54 , A61P35/00
Abstract: An object is to provide a technology that can stably exhibit the effects of A-type CpG oligodeoxynucleotides. The object can be achieved by a lipid particle comprising an A-type CpG oligodeoxynucleotide.
-
3.发明申请公开(公告)号：US20180223326A1
公开(公告)日：2018-08-09
申请号：US15579953
申请日：2016-06-17
Inventor： Yukihiro Akeda , Hiroshi Miyatake , Zhenyu Piao , Yuka Koizumi
IPC: C12Q1/18
CPC classification number: C12Q1/18 , C07K16/12 , C12N1/20 , G01N2333/3156
Abstract: The present invention relates to a measurement method for complement-dependent bactericidal activity against Streptococcus pneumoniae, and provides a measurement method capable of measuring complement-dependent bactericidal activity against Streptococcus pneumoniae of any capsular serotype. Complement-dependent bactericidal activity against Streptococcus pneumoniae is measured using capsule-deficient Streptococcus pneumoniae, that is, non-encapsulated or substantially non-encapsulated, or transparent Streptococcus pneumoniae. The measurement of the complement-dependent bactericidal activity against Streptococcus pneumoniae of any capsular serotype is enabled.
-
4.发明授权Human monoclonal antibodies broadly protective against influenza B virus and methods of using the same 有权广泛保护乙型流感病毒的人单克隆抗体及其使用方法公开(公告)号：US09181328B2
公开(公告)日：2015-11-10
申请号：US14375675
申请日：2013-01-31
Applicant: OSAKA UNIVERSITY , THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY , MEDICAL AND BIOLOGICAL LABORATORIES CO., LTD. , DEPARTMENT OF MEDICAL SCIENCES
Inventor： Mayo Yasugi , Motoki Kuhara , Jotika Boon-Long , Kazuhito Fujiyama , Ritsuko Koketsu , Kazuyoshi Ikuta
IPC: C07K16/10 , G01N33/569 , A61K39/00
CPC classification number: C07K16/1018 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/54 , C07K2317/565 , C07K2317/76 , C07K2317/92 , G01N33/56983 , G01N2333/11
Abstract: Materials and methods are provided for treating influenza B infections in humans. Anti-human influenza virus monoclonal antibodies and antigen-binding fragments thereof having a neutralization activity against a human influenza B virus are provided. Methods for producing anti-human influenza B virus monoclonal antibodies are also provided. The antibodies and antigen-binding fragments thereof can be effective against a wide range of influenza B viral strains. Methods of inhibiting or treating a human influenza B infection are provided. The anti-influenza B therapeutics can also be used to manufacture medicaments effective against influenza B infections, to detect human influenza B in a human subject, for use in pharmaceutical compositions, and for use in kits for at least one of the prevention, the treatment, and the detection of human influenza B in a human subject.
Abstract translation: 提供了用于治疗人类B型流感病毒的材料和方法。 提供了抗人流感病毒单克隆抗体及其对人类B型流感病毒具有中和活性的抗原结合片段。 还提供了产生抗人B型流感病毒单克隆抗体的方法。 抗体及其抗原结合片段对于广泛的乙型流感病毒株是有效的。 提供了抑制或治疗人流感B感染的方法。 抗乙型流感病毒治疗剂也可用于制造有效抗B型流感病毒的药物，以检测人类受试者中的人类流感B，用于药物组合物，并用于至少一种预防，治疗 ，以及人类受试者中人类乙型流感的检测。
-
5.发明申请HUMAN MONOCLONAL ANTIBODIES BROADLY PROTECTIVE AGAINST INFLUENZA B VIRUS AND METHODS OF USING THE SAME 有权人类单克隆抗体对流感病毒B病毒的广泛保护及其使用方法公开(公告)号：US20140377262A1
公开(公告)日：2014-12-25
申请号：US14375675
申请日：2013-01-31
Applicant: OSAKA UNIVERSITY , THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY , MEDICAL AND BIOLOGICAL LABORATORIES CO., LTD. , DEPARTMENT OF MEDICAL SCIENCES
Inventor： Mayo Yasugi , Motoki Kuhara , Jotika Boon-Long , Kazuhito Fujiyama , Ritsuko Koketsu , Kazuyoshi Ikuta
IPC: C07K16/10 , G01N33/569
CPC classification number: C07K16/1018 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/54 , C07K2317/565 , C07K2317/76 , C07K2317/92 , G01N33/56983 , G01N2333/11
Abstract: Materials and methods are provided for treating influenza B infections in humans. Anti-human influenza virus monoclonal antibodies and antigen-binding fragments thereof having a neutralization activity against a human influenza B virus are provided. Methods for producing anti-human influenza B virus monoclonal antibodies are also provided. The antibodies and antigen-binding fragments thereof can be effective against a wide range of influenza B viral strains. Methods of inhibiting or treating a human influenza B infection are provided. The anti-influenza B therapeutics can also be used to manufacture medicaments effective against influenza B infections, to detect human influenza B in a human subject, for use in pharmaceutical compositions, and for use in kits for at least one of the prevention, the treatment, and the detection of human influenza B in a human subject.
Abstract translation: 提供了用于治疗人类B型流感病毒的材料和方法。 提供了抗人流感病毒单克隆抗体及其对人类B型流感病毒具有中和活性的抗原结合片段。 还提供了产生抗人B型流感病毒单克隆抗体的方法。 抗体及其抗原结合片段对于广泛的乙型流感病毒株是有效的。 提供了抑制或治疗人流感B感染的方法。 抗乙型流感病毒治疗剂也可用于制造有效抗B型流感病毒的药物，以检测人类受试者中的人类流感B，用于药物组合物，并用于至少一种预防，治疗 ，以及人类受试者中人类乙型流感的检测。
-
Patent Agency Ranking
公开(公告)号：US09493550B2
公开(公告)日：2016-11-15
申请号：US14505515
申请日：2014-10-03
Inventor： Kazuyoshi Ikuta , Ritsuko Koketsu , Yoshinobu Okuno , Mikihiro Yunoki , Shoji Ideno , Masatoshi Oshita , Motoki Kuhara , Masatoshi Momota
CPC classification number: C07K16/1018 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/34 , C07K2317/76
Abstract: Provided is a human antibody having a neutralization activity against a human influenza virus. More specifically, provided is a human antibody which recognizes a highly conserved region in a human influenza A virus subtype H3N2 or a human influenza B virus and has a neutralization activity against the virus. The human antibody is a human anti-human influenza virus antibody, which has a neutralization activity against a human influenza A virus subtype H3N2 and binds to a hemagglutinin HA1 region of the human influenza A virus subtype H3N2, or which has a neutralization activity against a human influenza B virus, and includes, as a base sequence of a DNA encoding a variable region of the antibody, a sequence set forth in any one of SEQ ID NOS: 5 to 12.
-
7.发明申请NOVEL EPITOPE AND MECHANISM OF ANTIGEN-ANTIBODY INTERACTION IN AN INFLUENZA VIRUS 审中-公开流感病毒抗原抗体相互作用的新形象和机制公开(公告)号：US20140086927A1
公开(公告)日：2014-03-27
申请号：US14035495
申请日：2013-09-24
Applicant: Fujita Health University , The Research Foundation for Microbial Diseases of Osaka University , Osaka University
Inventor： Yoshikazu Kurosawa , Yoshitaka Iba , Nobuko Ohshima , Shigeyuki Yokoyama , Mikako Shirouzu , Yoshifumi Fujii , Tomomi Sumida , Kazuyoshi Ikuta , Shota Nakamura , Norihito Kawashita , Mitsuhiro Nishimura , Akifumi Yamashita , Yoshinobu Okuno , Ritsuko Kubota-Koketsu , Masahiro Okubo
IPC: C07K16/10 , G01N33/569
CPC classification number: C07K16/1018 , C07K2299/00 , C07K2317/21 , C07K2317/34 , C07K2317/55 , C07K2317/76 , G01N33/56983 , G01N2333/11 , G16B15/00 , G16C20/50
Abstract: Antibodies (Abs) play roles in protection against influenza. Neutralizing Abs either inhibit the binding of hemagglutinin (HA) to cellular receptors or prevent the conformational change of HA induced by low pH. The former Ab binds to the regions near the sialic acid-binding pocket on the globular head formed by HA1 and generally shows narrow strain specificity. The latter Ab binds to the stem region formed mainly by HA2 and shows broad strain specificity. We isolated a broadly neutralizing Ab against H3N2 viruses. X-ray analysis of the HA/Ab complex indicated that the Ab binds to the valley formed by two neighboring HA monomers at the side of the globular head. The Ab shows neutralizing activity by preventing the conformational change of HA induced at low pH.
Abstract translation: 抗体（Abs）在防止流行性感冒方面发挥作用。 中和抗体可抑制血细胞凝集素（HA）与细胞受体的结合，或阻止由低pH引起的HA的构象变化。 前者Ab与HA1形成的球形头上唾液酸结合口附近的区域结合，通常表现出狭窄的应变特异性。 后者Ab结合主要由HA2形成的茎区，并显示出广泛的应变特异性。 我们分离出一种广泛中和的Ab针对H3N2病毒。 HA / Ab复合物的X射线分析表明，Ab与球状头部侧面的两个相邻的HA单体形成的谷结合。 Ab通过防止在低pH下诱导的HA的构象变化来显示中和活性。
-
公开(公告)号：US12286573B2
公开(公告)日：2025-04-29
申请号：US16817352
申请日：2020-03-12
Applicant: MEKTEC CORPORATION , OSAKA UNIVERSITY
Inventor： Masayuki Iwase , Teppei Araki , Tsuyoshi Sekitani , Shusuke Yoshimoto
Abstract: To provide an adhesive sheet, the sheet increasing manufacturing efficiency of products including an adhesive agent layer, while using the adhesive agent layer to which an electro-conductive organic polymer compound is added. An adhesive sheet for use in applying a wiring board to a surface onto which the wiring board is to be applied, the adhesive sheet is constituted by an adhesive agent layer including an electro-conductive organic polymer compound and an adhesive material; a first releasing sheet provided on front surface of the adhesive agent layer; and a second releasing sheet provided on a back surface corresponding to a back surface of the front surface in the adhesive agent layer.
-
公开(公告)号：US12285600B2
公开(公告)日：2025-04-29
申请号：US17757966
申请日：2020-12-18
Applicant: OSAKA UNIVERSITY
Inventor： Seiji Kameda , Masayuki Hirata
Abstract: A resistance device (100) includes a field-effect transistor (TN) and a voltage applying circuit (1). The voltage applying circuit (1) applies a control voltage (Vgs) between the gate and source of the field-effect transistor (TN) according to a temperature (T) to control a resistance value (R) between the drain and source of the field-effect transistor (TN). The control voltage (Vgs) is a voltage obtained by adding a correction voltage (Vc) to a reference voltage (Vgs0). The correction voltage (Vc) depends on the temperature (T) and is set to be zero at a first temperature (T1).
-
公开(公告)号：US12264273B2
公开(公告)日：2025-04-01
申请号：US18464517
申请日：2023-09-11
Applicant: OSAKA UNIVERSITY , NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM , NICHIA CORPORATION
Inventor： Susumu Kuwabata , Taro Uematsu , Kazutaka Wajima , Tsukasa Torimoto , Tatsuya Kameyama , Daisuke Oyamatsu , Kenta Niki
IPC: C09K11/62 , B01J13/02 , B82Y30/00 , B82Y40/00 , C09B67/02 , C09K11/02 , G02F1/1335 , G02F1/13357 , H01L33/50
Abstract: A semiconductor nanoparticle includes a core and a shell covering a surface of the core. The shell has a larger bandgap energy than the core and is in heterojunction with the core. The semiconductor nanoparticle emits light when irradiated with light. The core is made of a semiconductor that contains M1, M2, and Z. M1 is at least one element selected from the group consisting of Ag, Cu, and Au. M2 is at least one element selected from the group consisting of Al, Ga, In and Tl. Z is at least one element selected from the group consisting of S, Se, and Te. The shell is made of a semiconductor that consists essentially of a Group 13 element and a Group 16 element.
-
-
-
-
-
-
-
-
-
Search Results
1738
records
(took 0.017 seconds)
